Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Romilkimab Biosimilar – Anti-IL13/IL4 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Romilkimab Biosimilar - Anti-IL13/IL4 mAb - Research Grade |
|---|---|
| Source | IMGT/mAb-DB 794 |
| Species | Human |
| Expression system | Mammalian cells |
| Molecular weight | LC: 36kDa HC: 63kDa |
| Purity | >95% |
| Buffer | PBS pH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | 4°C for short term; -20°C for long term |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | Romilkimab |
| Reference | PX-TA1027-SIL |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | [VH-VH' Gamma1 + VL-VL' kappa (bispecific) |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
Description of Stable Isotope Labelled Romilkimab Biosimilar - Anti-IL13/IL4 mAb - Research Grade
General information about Romilkimab
Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis, This product is for research use only.
Reviews
Il n’y a pas encore d’avis.